Form 4: Candel Therapeutics CEO Paul Peter Tak Sells Shares Under 10b5-1 Trading Plan
SEC Form 4
Candel Therapeutics CEO Paul Peter Tak sold a portion of his common stock holdings on March 18th and 19th, 2025, under a pre-arranged 10b5-1 trading plan.
Summary
- Paul Peter Tak, CEO of Candel Therapeutics, sold shares of common stock on March 18 and March 19, 2025.
- The sales were executed under a 10b5-1 trading plan adopted on November 19, 2024.
- On March 18, 2025, 25,772 shares were sold at a weighted average price of $8.7701, with prices ranging from $8.33 to $9.01.
- On March 19, 2025, 400 shares were sold at a weighted average price of $9.0025, with prices ranging from $9.00 to $9.01.
- Following these transactions, Tak directly owns 225,740 shares of Candel Therapeutics common stock.
Sentiment
Score: 5
Explanation: The document is a standard SEC Form 4 filing, indicating insider trading activity. The sentiment is neutral as it simply reports transactions without expressing any opinion on the company's performance or future prospects.
Industry Context
Sales by company insiders are a common occurrence, and the use of 10b5-1 trading plans allows insiders to sell shares over a period of time while avoiding concerns about insider trading. The market typically views these sales in the context of the overall financial health and prospects of the company.
Stakeholder Impact
- Shareholders may react to the news of the CEO selling shares, although the existence of a 10b5-1 plan mitigates concerns about the reasons for the sale.
Key Dates
| Date | Description |
|---|---|
| 11/19/2024 | Date of adoption of the 10b5-1 trading plan |
| 03/18/2025 | Date of first stock sale |
| 03/19/2025 | Date of second stock sale |
| 03/20/2025 | Date of Form 4 filing |
Keywords
Candel Therapeutics, Paul Peter Tak, stock sale, Form 4, 10b5-1 trading plan, CADL, CEO, insider trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.